SRR934877
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 97.3718791064389
- age_years
- 41
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.657
- INTERFERON_GAMMA_RESPONSE+0.559
- ALLOGRAFT_REJECTION+0.499
- PANCREAS_BETA_CELLS+0.416
- IL6_JAK_STAT3_SIGNALING+0.368
- KRAS_SIGNALING_UP+0.345
- MYC_TARGETS_V1+0.334
- COMPLEMENT+0.332
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.329
- INFLAMMATORY_RESPONSE+0.327
Top 10 suppressed
- MITOTIC_SPINDLE-0.313
- TGF_BETA_SIGNALING-0.220
- PI3K_AKT_MTOR_SIGNALING-0.191
- SPERMATOGENESIS-0.174
- APICAL_JUNCTION-0.156
- HEME_METABOLISM-0.149
- HEDGEHOG_SIGNALING-0.146
- NOTCH_SIGNALING-0.107
- PEROXISOME-0.106
- GLYCOLYSIS-0.094
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2377 | Med | Medulloblastoma | 0.868 |
| 2 | MDT-AP-0118 | Med | Medulloblastoma | 0.864 |
| 3 | TCGA-UY-A78P-01A-12R-A36F-07 | — | — | 0.844 |
| 4 | MDT-AP-1374 | Med | Medulloblastoma | 0.843 |
| 5 | AUR-AFUI-TTM1-A-1-0-R-A743-41 | — | C | 0.841 |
| 6 | MDT-AP-2131 | Med | Medulloblastoma | 0.820 |
| 7 | TCGA-D8-A1Y2-01A-11R-A157-07 | — | C | 0.814 |
| 8 | TCGA-33-4589-01A-01R-1443-07 | — | cohortSQ1 | 0.813 |
| 9 | AUR-AFUG-TTM1-A-1-1-R-A743-41 | — | C | 0.809 |
| 10 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.807 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.657 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.559 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.499 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.416 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.368 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.345 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.334 | Inavolisib | — uncovered |
| COMPLEMENT | 0.332 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.329 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.327 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.269 | Inavolisib | — uncovered |
| APOPTOSIS | 0.259 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.255 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.253 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.208 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.201 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.196 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.194 | Inavolisib | — uncovered |